Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. Financial Summary for the Third Quarter of the Fiscal Year Ending December 2026 [IFRS]
For the nine months ended the third quarter of the fiscal year ending December 2026, consolidated revenue was 1,068,074 million yen (YoY +17.2%), operating profit was 522,570 million yen (+21.6%), and net income was 375,302 million yen (+22.8%), all showing expansion. Full-year forecasts are maintained assuming revenue of 1,345,000 million yen, operating profit of 670,000 million yen on a Core basis, and a dividend of 66 yen. On a Core basis, revenue remains strong, supported by contributions from key products and new launches. Financial health metrics such as ROE and NOA remain solid. An earnings presentation will be held.
Key Figures
- Revenue: 1,068,074 million yen (Year-over-Year +17.2%)
- Operating Income: 522,570 million yen (Year-over-Year +21.6%)
- Quarterly Net Income: 375,302 million yen (Year-over-Year +22.8%)
AI要約
Overview of Results
Chugai Pharmaceutical reported revenue of 1,068,074 million yen for the third quarter of the fiscal year ending December 2026, marking a substantial increase year-over-year. Solid growth in sales of pharmaceutical products, together with contributions from overseas sales, drove the top-line increase. Core-based profit indicators also showed significant improvement. The IFRS results include effects such as amortization of intangible assets, but overall profitability improved. Supplementary materials and an IR briefing will be held online.
Outlook and Capital Allocation
Full-year forecasts are maintained at revenue of 1,345,000 million yen, Core-based operating income of 670,000 million yen, and a dividend of 66 yen. Growth of existing products and market penetration of new products are expected to continue, and the company intends to continue development investment while maintaining shareholder returns. Results through Q3 2026 support the achievement of the full-year forecasts, and financial soundness remains at a high level.
Revenue Trend
Operating Income Trend
Quarterly Net Income Trend
Domestic Product Sales Breakdown
Overseas Product Sales Breakdown
Chugai Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
